Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates

Core Insights - Co-Diagnostics, Inc. reported a quarterly loss of $0.24 per share, better than the Zacks Consensus Estimate of a loss of $0.33, and an improvement from a loss of $0.31 per share a year ago, resulting in an earnings surprise of 27.27% [1] - The company posted revenues of $0.05 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 86.84%, and down from $0.47 million in the same quarter last year [2] - Co-Diagnostics shares have declined approximately 53.3% year-to-date, contrasting with the S&P 500's decline of 4.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $0.38 million, and for the current fiscal year, it is -$0.91 on revenues of $1.5 million [7] - The estimate revisions trend for CoDiagnostics is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, Surgery Partners, is expected to report quarterly earnings of $0.08 per share, reflecting a year-over-year decline of 20%, with revenues projected at $796.68 million, an increase of 11.1% from the previous year [9][10]